Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司自愿披露关于美国食品药品监督管理局批准百悦达用于复发难治性套细胞淋巴瘤治疗的公告
Regulatory Filings Classification · 85% confidence The document is a voluntary disclosure announcement by BeiGene regarding FDA accelerated approval of their drug Beqelzi for relapsed/refractory mantle cell lymphoma. It contains no financial statements, no voting outcomes, no management or board changes, nor any form 10-K, earnings release, or financing update. It is a routine regulatory announcement of a material event under stock‐exchange disclosure rules, making it a general Regulatory Filing (RNS).
2026-05-13 Chinese
港股公告：授出受限制股份单位
Share Issue/Capital Change Classification · 85% confidence The document is a Hong Kong Stock Exchange announcement under Listing Rules 17.06A/B/C regarding the grant of restricted share units (RSUs) under the company’s 2016 Option and Incentive Plan. It details the issue of new American Depositary Shares (equivalent to ordinary shares), vesting schedule, and total shares to be issued. This is an announcement of a capital change (issuance of shares) rather than financial statements, management discussion, or other categories. Therefore, it falls under Share Issue/Capital Change (Code: SHA).
2026-05-13 Chinese
美股公告：表格S-3
Regulatory Filings
2026-05-07 Chinese
美股公告：表格S-3
Regulatory Filings
2026-05-07 Chinese
港股公告：证券变动月报表
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report submitted to the Hong Kong Stock Exchange (HKEX) under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirms compliance with public float requirements. It includes specific data on share capital, share options, and confirmations by the company's executive director and CEO. The document is titled as a monthly report and does not contain financial statements or management discussion. It is a regulatory compliance filing related to share capital and securities movements rather than a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS). The document length (5724 characters) and detailed content confirm it is not a brief announcement but a formal regulatory report.
2026-05-07 Chinese
百济神州有限公司自愿披露关于2026年度经营业绩预测调整的公告
Regulatory Filings
2026-05-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.